Levacetylleucine significantly improves neurological symptoms and functioning in patients with ataxia-telangiectasia, according to results from the IB1001-303 clinical trial. Topline results were ...
Ataxia-Telangiectasia (A-T) is a rare, inherited, progressive neurodegenerative disorder that typically begins in early childhood. A-T is characterized by degeneration of the cerebellum, leading to ...
IntraBio Inc. today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for levacetylleucine for the treatment of ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Quince Therapeutics, Inc. (QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of ...
Having a rare genetic disease is actually pretty common. Rare diseases affect approximately 1 in 10 individuals, and more than 30 million people in the U.S. have a rare disease diagnosis. What makes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results